Abstract:BACKGROUND/AIMS:Minimal residual leukemia cells (MRLs) are difficult to eradicate through traditional treatment and therefore remain to be a major threat to the long-term survival of leukemia patients. Tumor-derived exosomes (TEXs), which carry tumor associated antigens (TAA), may be a potential cell-free tumor vaccine for the specific eradication of MRLs. However, TEXs are intended to be less immunogenic due to exosomal TGF-β1. To further optimize the efficacy of TEX-based vaccines, we investigated whether exosomes from TGF-β1 silenced leukemia cells (LEXTGF-β1si) had an increased potential to induce a specific antitumor effect compared with non-modified exosomes.METHODS:Exosomal TGF-β1 was downregulated via lentiviral shRNA silencing of TGF-β1 in leukemia cells. The characteristics of LEXTGF-β1si were determined via electron microscopy, western blot analysis, and flow cytometry. The antitumor effect of LEXTGF-β1si was evaluated by detecting the properties of LEXTGF-β1si-pulsed dendritic cells (DCs), CD4+ T-cell proliferation, Th1 cytokine secretion, specific CTL activity, and NK cell function. Moreover, to verify the superiority of LEXTGF-β1si immunization, LEXTGF-β1si was subcutaneously injected into DBA/2 mice: either followed by tumor challenge or tumor bearing.RESULTS:The lentiviral shRNA silencing of TGF-β1 in parental leukemia cells successfully downregulated the TGF-β1 level in leukemia cell derived exosomes (LEX). LEXTGF-β1si was uptaken by DCs and was more potent in promoting DC function by upregulating the surface expression of costimulatory factors and MHC class II molecules, while inducing the secretion of IL-12p70 and TNF-α. Furthermore, immunization with LEXTGF-β1si facilitated CD4+ T-cell proliferation and Th1 cytokine secretion, and stimulated stronger specific cytotoxic lymphocyte (CTL) response and nature killer (NK) cell cytotoxicity more efficiently compared to non-modified LEX. In mice models, immunization with LEXTGF-β1si resulted in a more potent capability to inhibit tumor growth and to prolong survival, suggesting that LEXTGF-β1si was more effective in both protective and therapeutic antitumor tests than non-modified LEX.CONCLUSIONS:These data suggested that down-regulation of exosomal TGF-β1 effectively induced potent anti-tumor immunity. Our strategy of optimizing exosome vaccine may have promising potential for leukemia immunotherapy.

A Novel Costimulatory Molecule Gene-Modified Leukemia Cell-Derived Exosome-Targeted CD4+ T Cell Vaccine Efficiently Enhances Anti-Leukemia Immunity

A novel costimulatory molecule gene-modified leukemia cell-derived exosome enhances the anti-leukemia efficacy of DC vaccine in mouse models

Enhanced Immunogenicity of Leukemia-Derived Exosomes Via Transfection with Lentiviral Vectors Encoding Costimulatory Molecules

More efficient induction of antitumor T cell immunity by exosomes from CD40L gene-modified lung tumor cells.

Enhancing the Anti-Leukemia Immunity of Acute Lymphocytic Leukemia-Derived Exosome-Based Vaccine by Downregulation of PD-L1 Expression

Enhancement of Anti-Leukemia Immunity by Leukemia–Derived Exosomes Via Downregulation of TGF-β1 Expression

TGF-β1-silenced leukemia cell-derived exosomes target dendritic cells to induce potent anti-leukemic immunity in a mouse model

Dendritic Cells Pulsed with Leukemia Cell-Derived Exosomes More Efficiently Induce Antileukemic Immunities.

Leukemia Cell-Derived Exosomes Targeted Dendritic Cells Can Induce More Strong Anti-Leukemia Response Than Exosomes Alone

Enhanced induction of dendritic cell maturation and HLA-A*0201-restricted CEA-specific CD8 + CTL response by exosomes derived from IL-18 gene-modified CEA-positive tumor cells

Biological properties of leukemia cell-derived exosome and anti-leukemia effects of its sensitized DCs

Efficient activation of antitumor immunity by IL-6 gene-modified leukemia vaccine in combination with low dose cyclophosphamide and low dose IL-2

Abstract 1561: Leukemia Cell-Derived Exosomes Targeted Dendritic Cells Can Induce More Strong Anti-Leukemia Response Than Exosomes Alone

A Novel HER-2-specific Exosome-Targeted T Cell-Based Vaccine: Immunotherapy of Established Lung Metastasis in Transgenic HLA-A2/HER-2 Mice (155.37)

[Effect of CTL on K562 Cell Induced by Exosomes and in Combination with CPG OND].

Studies on biological properties and effects of anti-lymphoma of lymphoma cell-derived exosomes

Novel Exosome-Targeted Cd4(+) T Cell Vaccine Counteracting Cd4(+)25(+) Regulatory T Cell-Mediated Immune Suppression and Stimulating Efficient Central Memory Cd8(+) Ctl Responses

Efficient induction of antitumor T cell immunity by exosomes derived from heat-shocked lymphoma cells.

Tumor Cell-associated Exosomes Robustly Elicit Anti-tumor Immune Responses through Modulating Dendritic Cell Vaccines in Lung Tumor

Lymphotactin Gene-Modified Bone Marrow Dendritic Cells Act As More Potent Adjuvants for Peptide Delivery to Induce Specific Antitumor Immunity

Large-Scale Expansion of Leukemia Specific CTLs Using Lysates-Pulsed Dendritic Cell and Low-Dose IL-2 for Adoptive Immunotherapy